Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Paper
  • Published:

New drug policy in childhood obesity

International Journal of Obesity volume 29, pages S62–S65 (2005)Cite this article

Abstract

OBJECTIVE:

To update physicians, especially paediatricians, in the rapidly developing field of pharmacotherapy of childhood and adolescent obesity.

METHODS:

The paper reviews current and investigational antiobesity drugs.

RESULTS:

At present, there are only few drugs approved by the Food and Drug Administration (FDA) for the treatment of adult obesity. The most important ones are sibutramine and orlistat. The FDA in the USA approved the latter drug in 2003, and it has recently been approved by the European Union for the treatment of adolescents. There are several investigational antiobesity agents but only few new and promising substances like Rimonabant (a cannabinoid receptor antagonist) and axokine (ciliary neutrotrophic factor) are already at an advanced stage of development.

CONCLUSION:

In adults, it seems to be justified using drugs for long-term treatment of ‘medically important’ obesity. Strict guidelines concerning the treatment of obese adolescents with orlistat are needed. It is only hoped that double-blind placebo-controlled studies investigating the new and promising drugs will also include adolescents and provide sufficient scientific data to get them licensed for the treatment of obese adolescents.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Ogden CL, Flegal KM, Carroll MD, Johnson CL . Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 2002; 288: 1728–1732.

    Article  Google Scholar 

  2. Booth ML, Wake M, Armstrong T, Chey T, Hesketh K, Mathur S . The epidemiology of overweight and obesity among Australian children and adolescents, 1995–97. Aust NZ J Public Health 2001; 25: 162–169.

    Article  CAS  Google Scholar 

  3. Watkins DC, Murray LJ, McCarron P, Boreham CAG, Cran GW, Young IS, McGartland C, Robson PJ, Savage JM . Ten-year trends for fatness in Northern Irish adolescents: the Young Hearts Projects—repeat cross-sectional study. Int J Obes Relat Metab Disord 2005; 29: 579–585.

    Article  CAS  Google Scholar 

  4. Al-Haddad FH, Little BB, Abdul Ghafoor AG . Childhood obesity in United Arab Emirates schoolchildren: a national study. Ann Hum Biol 2005; 32: 72–79.

    Article  Google Scholar 

  5. Epstein LH, Valoski AM, Kalarchian MA, McCurley J . Do children lose and maintain weight easier than adults: a comparison of child and parent weight changes from six months to ten years. Obes Res 1995; 3: 411–417.

    Article  CAS  Google Scholar 

  6. Epstein LH, Valoski AM, Wing RR, McCurley J . Ten-yer outcomes of behavioural family-based treatment for childhood obesity. Health Psychol 1994; 13: 373–383.

    Article  CAS  Google Scholar 

  7. Finer N . Present and future pharmacologic approaches. Brit Med Bull 1997; 53: 409–432.

    Article  CAS  Google Scholar 

  8. Ryan DH, Kaiser P, Bray GA . Sibutramine: a novel new agent for obesity treatment. Obes Res 1995; 3 (Suppl 4): 553–559.

    Article  Google Scholar 

  9. James WTP, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WHM, VanGaal LF . Effect of Sibutramine on weight maintenance after weight loss: a randimized trial. Lancet 2000; 356: 2119–2125.

    Article  CAS  Google Scholar 

  10. Wirth A, Krause J . Long-term weight loss with sibutramine. JAMA 2001; 286: 1331–1339.

    Article  CAS  Google Scholar 

  11. Dujovne CA, Zavoral JH, Rowe E, Memdel CM . Effects of sibutramine on body weight and serum lipids. Am Heart J 2001; 142: 489–497.

    Article  CAS  Google Scholar 

  12. Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J . Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo controlled study. Diabet Obes Metab 2000; 2: 105–112.

    Article  CAS  Google Scholar 

  13. Kim SH, Lee YM, Jee SH, Nam CM . Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 2003; 11: 1116–1123.

    Article  CAS  Google Scholar 

  14. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL . Behavior therapy and sibutramine for the treatment of adolescent obesity. JAMA 2003; 289: 1805–1812.

    Article  CAS  Google Scholar 

  15. Godoy-Matos A, Carraro L, Vieira A, Oliviera A, Gues EP, Mattos L, Rangel C, Moreira RO, Coutimho W, Appolinario JC . Treatment of adolescents with sibutramine: a randomised, doule-blind, controlled study. J Clin Endocrinol Metab 2005; 90: 1460–1465.

    Article  CAS  Google Scholar 

  16. Guerciolini R . Mode of action of orlistat. Int J Obes Relat Metab Disord 1997; 21 (Suppl 3): S12–S23.

    CAS  PubMed  Google Scholar 

  17. Sjöström L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar HPF, Krempf M . Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. Lancet 1998; 352: 160–161.

    Article  Google Scholar 

  18. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JPH, Sjostrom L . Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321–1326.

    Article  CAS  Google Scholar 

  19. Rössner S, Sjöström L, Noack R, Meinders AE, Noseda G . Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000; 8: 49–61.

    Article  Google Scholar 

  20. McDuffie JR, Calis KA, Uwaifo GI, Sebring NG, Fallon EM, Hubbard VS, Yanovski JA . Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002; 10: 642–650.

    Article  CAS  Google Scholar 

  21. Ozkan B, Bereket A, Turan S, Keskin S . Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr 2004; 163: 738–741.

    Article  Google Scholar 

  22. Norgren S, Danielsson P, Jurold R, Lotborn M, Marcus C . Orlistat treatment in obese prepubertal children: pilot study. Acta Paediatr 2003; 92: 666–670.

    Article  CAS  Google Scholar 

  23. Chanoine JP, Hauptman J, Boldrin M, Smith D, Hampl S . Beneficial effects of orlistat on weight and body composition in obese adolescents. Int J Obes Relat Metab Disord 2004; 28 (Suppl 1): S195.

    Google Scholar 

  24. Chanoine JP, Hampl S, Jensen C, Boldrin M, Hauptman J . Effects of orlistat on weight and body composition in obese adolescents: a randomised controlled trial. JAMA 2005; 293: 2873–2883.

    Article  CAS  Google Scholar 

  25. Bays HE . Current and investigational antiobesity agents and obesity therapeutic treatment targets. Obes Res 2004; 12: 1197–1211.

    Article  CAS  Google Scholar 

  26. Astrup A, Toubro S . Topiramate: a new potential pharmacological treatment for obesity. Obes res 2004; 12: 167S–173S.

    Article  CAS  Google Scholar 

  27. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S . Effects of the cannabionid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005; 365: 1363–1364.

    Article  Google Scholar 

  28. Caro JF, Sinha MK, Kolaczynski JW, Zhang PL, Considine RV . Leptin: the tale of an obesity gene. Diabetes 1996; 45: 1455–1462.

    Article  CAS  Google Scholar 

  29. Dallongeville J, Fruchart J-Ch, Auwerx J . Leptin, a pleiotropic hormone: physiology, pharmacology, and strategies for discovery of leptin modulators. J Med Chem 1998; 41: 5337–5352.

    Article  CAS  Google Scholar 

  30. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S . Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999; 341: 879–884.

    Article  CAS  Google Scholar 

  31. Pérusse L, Rankinen T, Zuberi A, Chagnon YC, Weisnagel SJ, Argyropoulos G, Walts B, Snyder EE, Bouchard C . The human obesity gene map: The 2004 update. Obes Res 2005; 13: 381–490.

    Article  Google Scholar 

  32. Gibson WT, Farooqi IS, Moreau M, DePaoli AM, Lawrence E, O'Rahilly S, Trussell RA . Congenital leptin deficiency due to homozygosity for the delta133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab 2004; 89: 4821–4826.

    Article  CAS  Google Scholar 

  33. Heymsfield SB, Greenberg AS, Fujoka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCanish M . Recombinant leptin for weight loss in obese and lean adults. JAMA 1999; 282: 1568–1575.

    Article  CAS  Google Scholar 

  34. Hukshorn CJ, Saris WH, Westerterp-Plantenga MS, farid AR, Smith FJ, Campfield LA . Weekly subcutaneous pegylated recombinant native human leptin (PEG-OB) administration in obese men. J Clin Endocrinol Metab 2000; 85: 4003–4009.

    Article  CAS  Google Scholar 

  35. Ettinger MP, Littlejohn TW, Schwartz SL, Weiss SR, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Heyman ER, Stambler N, Heshka S, Vicary C, Guler HP . Recombinant variant of ciliary neurotrophic factor for weight loss in obese adults: a randomized, dose-ranging study. JAMA 2003; 289: 1826–1832.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Paediatrics, University of Pécs, Hungary, Pécs, Hungary

    D Molnár

Authors
  1. D Molnár
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D Molnár.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molnár, D. New drug policy in childhood obesity. Int J Obes 29 (Suppl 2), S62–S65 (2005). https://doi.org/10.1038/sj.ijo.0803084

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijo.0803084

Keywords

This article is cited by

Search

Advanced search

Quick links